Search

Your search keyword '"Oncogenesis Stress Signaling (OSS)"' showing total 179 results

Search Constraints

Start Over You searched for: Author "Oncogenesis Stress Signaling (OSS)" Remove constraint Author: "Oncogenesis Stress Signaling (OSS)"
179 results on '"Oncogenesis Stress Signaling (OSS)"'

Search Results

1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1

2. Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations

3. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial

4. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

5. Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

6. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

7. The Appendix Orchestrates T-Cell Mediated Immunosurveillance in Colitis-Associated Cancer

8. Cancer de l’ovaire : la rechute précoce

9. LARS2 variants can present as premature ovarian insufficiency in the absence of overt hearing loss

10. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

11. Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC

12. A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment

13. Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer

14. Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score‐matched study from the <scp>FRANCOGYN</scp> group

15. Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic nonsmall-cell lung cancer: a secondary analysis of ESOGIA-GFPC-GECP 08-02 Study

16. A LOW BASELINE BLOOD NEUTROPHIL COUNT AND A HIGH PERCENTAGE OF TREG AMONG LEUCOCYTES ARE ASSOCIATED WITH AN INCREASED OVERALL SURVIVAL OF RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH BEVACIZUMAB

17. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors–Short Text

18. A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney

19. Recommandations pour la pratique clinique : tumeurs bénignes du sein – Objectifs, méthodes et organisation [Clinical practice guidelines: Benign breast tumor – Aims, methods and organization]

20. Dominant TP63 missense variants lead to constitutive activation and premature ovarian insufficiency

21. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

22. 188Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)

23. Transversus Abdominis Plane Block for Anterior Lumbar Interbody Fusion: a randomized controlled trial

24. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

25. Cefotaxime resistance in bile samples is an independent predictor of deep infectious complications after pancreaticoduodenectomy in patients with endoprosthesis

26. A novel optinEuRin stress connection in glaucoma

27. Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer

28. Virtual Reality as a Hypnotic Tool in the Management of Anxiety During the Performance of the Axillary Block

29. GLI1, a novel target of the ER stress regulator p97/VCP, promotes ATF6f-mediated activation of XBP1

30. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

31. Criteria for preclinical models of cholangiocarcinoma:scientific and medical relevance

32. Risk factors associated with early and late free flap complications in head and neck osseous reconstruction

33. Difficulties for providing evidence in hepatocellular carcinoma with Child-Pugh B liver function

34. Chemotherapy with ceramide in TNBC

35. Tumeurs bénignes du sein : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) – Texte court [Benign breast tumors: Recommendations of Collège National des Gynécologues Obstétriciens Français (CNGOF) – Short text]

36. Adaptation of the secretory pathway in cancer through IRE1 signaling

37. Pulmonary manifestations induced by osimertinib

38. Metalloprotease-mediated cleavage of CD95 Ligand

39. Adjuvant treatment for biliary tract tumours: lost in a maze?

40. Functional Assessment of a New PBX1 Variant in a 46,XY Fetus with Severe Syndromic Difference of Sexual Development through CRISPR-Cas9 Gene Editing

41. Challenges in glioblastoma research: focus on the tumor microenvironment

42. Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient

43. Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD)

44. A TRAFFIC themed series - Host membrane trafficking subversion by pathogens

45. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

46. IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response

47. Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review

48. New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations

49. Dommages à l’ADN et ondes millimétriques: Analyse de la voie de réponse aux dommages à l’ADN en réponse à une co-exposition comprenant les ondes millimétriques

50. Apport de l'immunothérapie dans le traitement des cancers des voies biliaires avancés

Catalog

Books, media, physical & digital resources